CEDIPROF INC is a specialty pharmaceutical company focused on Oncology, Metabolic.
CEDIPROF INC's Key Drugs
CEDIPROF INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CEDIPROF INC's Recent FDA Approvals
New NDA/BLA approvals for CEDIPROF INC over the last two years — novel drugs only, excluding generics and label supplements.
CEDIPROF INC's Therapeutic Areas
CEDIPROF INC's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CEDIPROF INC's Top Competitors
CEDIPROF INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CEDIPROF INC Pipeline Snapshot
Active clinical trials for CEDIPROF INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2002-03-01
- Latest
- 2026-05-04
- Applications
- 5